The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface Exposure
Open accessAbstract
Both theory and clinical studies demonstrate that drug concentrations in the peritoneal cavity can greatly exceed concentrations in the plasma following intraperitoneal administration. This regional advantage has been associated with clinical activity, including surgically documented complete responses in ovarian cancer patients with persistent or recurrent disease following systemic therapy, and has produced a survival advantage in a recent phase III trial. Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration by the drug and incomplete irrigation of serosal surfaces by the drug-containing solution. We have examined these problems in the context of a very simple, spatially distributed model. If D is the diffusivity of the drug in a tissue adjacent to the peritoneal cavity and k is the rate constant for removal of the drug from the tissue by capillary blood, the model predicts that (for slowly reacting drugs) the characteristic penetration distance is (D/k)1/2 and the apparent permeability of the surface of a peritoneal structure is (Dk)1/2. The permeability-area product used in classical pharmacokinetic calculations for the peritoneal cavity as a whole is the sum of the products of the tissue-specific permeabilities and the relevant superficial surface areas. Since the model is mechanistic, it provides insight into the expected effect of procedures such as pharmacologic manipulation or physical mixing. We observe that large changes in tissue penetration may be difficult to achieve but that we have very little information on the transport characteristics within tumors in this setting or their response to vasoactive drugs. Enhanced mixing is likely to offer significant potential for improved therapy; however, procedures easily applicable to the clinical setting have not been adequately investigated and should be given high priority. Clinical studies indicate that an increase in irrigated area may be achieved in many patients by individualizing the dialysate volume and consideration of patient position.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., & Jain, R. K. (1995) · PubMed · Cited by 1,711
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Rl, D., Ce, M., Bungay, P. M., & Vt, D. (1978) · PubMed · Cited by 735
Transport of macromolecules across microvascular walls: the two-pore theory
Rippe, B., & Haraldsson, B. (1994) · Physiological Reviews · doi:10.1152/physrev.1994.74.1.163 · Cited by 560
Chary, S. R., & Jain, R. K. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.14.5385 · Cited by 411
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Markman, M., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J. L., Rubin, S., Curtin, J., Barakat, R., & Phillips, M. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.9.1485 · Cited by 313
Pharmacologic Principles of Cancer Treatment.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-5-694_1 · Cited by 304
The Textbook of Peritoneal Dialysis
(1994) · Springer eBooks · doi:10.1007/978-94-011-0814-0 · Cited by 266
Bulk transfer of fluid in the interstitial compartment of mammary tumors.
Butler, T. P., Grantham, F. H., & Gullino, P. M. (1975) · PubMed · Cited by 203
Francis, P. A., Rowinsky, E. K., Schneider, J., Hakes, T. B., Hoskins, W. J., & Markman, M. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2961 · Cited by 191
Markman, M., Reichman, B., Hakes, T., Jones, W., Lewis, J. L., Rubin, S., Almadrones, L., & Hoskins, W. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.10.1801 · Cited by 191
Roh, H., Boucher, Y., Kalnicki, S., Buchsbaum, R., Bloomer, W. D., & Jain, R. K. (1991) · PubMed · Cited by 180
(1993) · PubMed · Cited by 166
Taxol: a history of pharmaceutical development and current pharmaceutical concerns.
Adams, J. D., Flora, K. P., Goldspiel, B. R., Wilson, J., Arbuck, S. G., & Finley, R. W. (1993) · PubMed · Cited by 157
Chemical modification of tumour blood flow
Jirtle, R. L. (1988) · International Journal of Hyperthermia · doi:10.3109/02656738809016490 · Cited by 133
Transactions of the American Society for Artificial Internal Organs.
Barnes, B. A. (1965) · Archives of Internal Medicine · doi:10.1001/archinte.1965.03860150108026 · Cited by 109
Interspecies Scaling of Regional Drug Delivery
Dedrick, R. L. (1986) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600751106 · Cited by 92
Self-citationZlotecki, R. A., Baxter, L. T., Boucher, Y., & Jain, R. K. (1995) · Microvascular Research · doi:10.1006/mvre.1995.1069 · Cited by 91
Blood flow and venous pH of tissue-isolated Walker 256 carcinoma during hyperglycemia.
Sevick, E., & Jain, R. K. (1988) · PubMed · Cited by 64
Experimental and clinical status of intraperitoneal chemotherapy
Los, G., & McVie, J. G. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90137-i · Cited by 61
Effects of a TV Drama Series upon Public Impressions about Psychiatrists
Sancho-Aldridge, J., & Gunter, B. (1994) · Psychological Reports · doi:10.2466/pr0.1994.74.1.163 · Cited by 45
Tumour blood flow: measurement and manipulation for therapeutic gain
Sagar, S. M., Klassen, G. A., Barclay, K. D., & Aldrich, J. E. (1993) · Cancer Treatment Reviews · doi:10.1016/0305-7372(93)90009-g · Cited by 40
Flessner, M. F., & Dedrick, R. L. (1994) · PubMed · Cited by 27
Self-citationGlucose effects in an ovarian cancer protocol of exceptional activity
Scheim, D. E., & Lin, J. (1993) · Medical Hypotheses · doi:10.1016/0306-9877(93)90048-u · Cited by 4
Cited by
Wilens, T. E., Faraone, S. V., Biederman, J., & Gunawardene, S. (2003) · Pediatrics · doi:10.1542/peds.111.1.179 · Cited by 872
Earle, C. C., & Maroun, J. A. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00076-3 · Cited by 411
Solass, W., Kerb, R., Mürdter, T., Giger-Pabst, U., Strumberg, D., Tempfer, C., Zieren, J., Schwab, M., & Reymond, M. A. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3213-1 · Cited by 385
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
Alyami, M., Hübner, M., Grass, F., Bakrin, N., Villeneuve, L., Laplace, N., Passot, G., Glehen, O., & Kepenekian, V. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30318-3 · Cited by 331
Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients
Levine, E. A., Stewart, J. H., Shen, P., Russell, G. B., Loggie, B. L., & Votanopoulos, K. I. (2014) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.12.013 · Cited by 270
Metadata
- Authors
- Dedrick, R. L., & Flessner, M. F.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1997-04-02
- Volume
- 89
- Issue
- 7
- Pages
- 480-487
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2162553170
- Cited by
- 305
- References
- 27
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.